A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

NCT07475026 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

198

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG: Tislelizumab
DRUG: Lenvatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital